Literature DB >> 26223493

Modulatory effects of ketamine, risperidone and lamotrigine on resting brain perfusion in healthy human subjects.

Sergey Shcherbinin1, Orla Doyle2, Fernando O Zelaya2, Sara de Simoni2, Mitul A Mehta2, Adam J Schwarz3.   

Abstract

RATIONALE: Resting brain perfusion, measured using the MRI-based arterial spin labelling (ASL) technique, is sensitive to detect central effects of single, clinically effective, doses of pharmacological compounds. However, pharmacological interaction experiments, such as the modulation of one drug response in the presence of another, have not been widely investigated using a task-free ASL approach.
OBJECTIVES: We assessed the effects of three psychoactive compounds (ketamine, risperidone and lamotrigine), and their interaction, on resting brain perfusion in healthy human volunteers.
METHODS: A multivariate Gaussian process classification (GPC) and more conventional univariate analyses were applied. The four pre-infusion conditions for each subject comprised risperidone, lamotrigine and two placebo sessions. The two placebo conditions enabled us to evaluate the classification performance in a test-retest setting, in addition to its performance in distinguishing the active oral drugs from placebo (direct effect on brain perfusion). The post ketamine- or saline-infusion scans allowed the effect of ketamine, and its interaction with risperidone and lamotrigine, on brain perfusion to be characterised.
RESULTS: The pseudo-continuous ASL measurements of perfusion were sensitive to the effects of ketamine infusion and risperidone. The GPC captured consistent changes in perfusion across the group and contextualised the univariate changes with a larger pattern of regions contributing to accurate discrimination of ketamine from placebo.
CONCLUSIONS: The findings argue against perfusion changes confounding in the previously described evoked BOLD response to ketamine and emphasise the blockade of the NMDA receptor over neuronal glutamate release in determining the perfusion changes induced by ketamine.

Entities:  

Keywords:  Brain imaging; Drug; MRI; Mapping; Modulation; Patterning; Recognition; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26223493     DOI: 10.1007/s00213-015-4021-z

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  36 in total

1.  Brain serotonin 5-HT(1A) receptor binding in schizophrenia measured by positron emission tomography and [11C]WAY-100635.

Authors:  Johannes Tauscher; Shitij Kapur; N Paul L G Verhoeff; Douglas F Hussey; Zafiris J Daskalakis; Sitra Tauscher-Wisniewski; Alan A Wilson; Sylvain Houle; Siegfried Kasper; Robert B Zipursky
Journal:  Arch Gen Psychiatry       Date:  2002-06

2.  Quantitative prediction of subjective pain intensity from whole-brain fMRI data using Gaussian processes.

Authors:  Andre Marquand; Matthew Howard; Michael Brammer; Carlton Chu; Steven Coen; Janaina Mourão-Miranda
Journal:  Neuroimage       Date:  2009-10-29       Impact factor: 6.556

3.  Ketamine interactions with biomarkers of stress: a randomized placebo-controlled repeated measures resting-state fMRI and PCASL pilot study in healthy men.

Authors:  Najmeh Khalili-Mahani; Marieke Niesters; Matthias J van Osch; Melly Oitzl; Ilya Veer; Mark de Rooij; Joop van Gerven; Mark A van Buchem; Christian F Beckmann; Serge A R B Rombouts; Albert Dahan
Journal:  Neuroimage       Date:  2014-12-29       Impact factor: 6.556

4.  Pseudo-continuous arterial spin labeling MRI study of schizophrenic patients.

Authors:  Miho Ota; Masanori Ishikawa; Noriko Sato; Mitsutoshi Okazaki; Norihide Maikusa; Hiroaki Hori; Kotaro Hattori; Toshiya Teraishi; Kimiteru Ito; Hiroshi Kunugi
Journal:  Schizophr Res       Date:  2014-02-26       Impact factor: 4.939

5.  Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents.

Authors:  O M Doyle; S De Simoni; A J Schwarz; C Brittain; O G O'Daly; S C R Williams; M A Mehta
Journal:  J Pharmacol Exp Ther       Date:  2013-01-31       Impact factor: 4.030

6.  Test-retest reliability of the BOLD pharmacological MRI response to ketamine in healthy volunteers.

Authors:  S De Simoni; A J Schwarz; O G O'Daly; A F Marquand; C Brittain; C Gonzales; S Stephenson; S C R Williams; M A Mehta
Journal:  Neuroimage       Date:  2012-09-23       Impact factor: 6.556

7.  The interactive effects of ketamine and nicotine on human cerebral blood flow.

Authors:  Laura M Rowland; Lori Beason-Held; Carol A Tamminga; Henry H Holcomb
Journal:  Psychopharmacology (Berl)       Date:  2010-03       Impact factor: 4.530

8.  Ketamine-Induced Modulation of the Thalamo-Cortical Network in Healthy Volunteers As a Model for Schizophrenia.

Authors:  Anna Höflich; Andreas Hahn; Martin Küblböck; Georg S Kranz; Thomas Vanicek; Christian Windischberger; Alois Saria; Siegfried Kasper; Dietmar Winkler; Rupert Lanzenberger
Journal:  Int J Neuropsychopharmacol       Date:  2015-04-19       Impact factor: 5.176

9.  The psychedelic state induced by ayahuasca modulates the activity and connectivity of the default mode network.

Authors:  Fernanda Palhano-Fontes; Katia C Andrade; Luis F Tofoli; Antonio C Santos; Jose Alexandre S Crippa; Jaime E C Hallak; Sidarta Ribeiro; Draulio B de Araujo
Journal:  PLoS One       Date:  2015-02-18       Impact factor: 3.240

10.  Circadian and homeostatic modulation of functional connectivity and regional cerebral blood flow in humans under normal entrained conditions.

Authors:  Duncan J Hodkinson; Owen O'Daly; Patricia A Zunszain; Carmine M Pariante; Vitaly Lazurenko; Fernando O Zelaya; Matthew A Howard; Steven C R Williams
Journal:  J Cereb Blood Flow Metab       Date:  2014-06-18       Impact factor: 6.200

View more
  12 in total

Review 1.  Searching for Cross-Diagnostic Convergence: Neural Mechanisms Governing Excitation and Inhibition Balance in Schizophrenia and Autism Spectrum Disorders.

Authors:  Jennifer H Foss-Feig; Brendan D Adkinson; Jie Lisa Ji; Genevieve Yang; Vinod H Srihari; James C McPartland; John H Krystal; John D Murray; Alan Anticevic
Journal:  Biol Psychiatry       Date:  2017-03-14       Impact factor: 13.382

Review 2.  Ketamine-Associated Brain Changes: A Review of the Neuroimaging Literature.

Authors:  Dawn F Ionescu; Julia M Felicione; Aishwarya Gosai; Cristina Cusin; Philip Shin; Benjamin G Shapero; Thilo Deckersbach
Journal:  Harv Rev Psychiatry       Date:  2018 Nov/Dec       Impact factor: 3.732

Review 3.  The role of fMRI in drug development.

Authors:  Owen Carmichael; Adam J Schwarz; Christopher H Chatham; David Scott; Jessica A Turner; Jaymin Upadhyay; Alexandre Coimbra; James A Goodman; Richard Baumgartner; Brett A English; John W Apolzan; Preetham Shankapal; Keely R Hawkins
Journal:  Drug Discov Today       Date:  2017-11-15       Impact factor: 7.851

4.  Default Mode Connectivity in Major Depressive Disorder Measured Up to 10 Days After Ketamine Administration.

Authors:  Jennifer W Evans; Joanna Szczepanik; Nancy Brutsché; Lawrence T Park; Allison C Nugent; Carlos A Zarate
Journal:  Biol Psychiatry       Date:  2018-02-15       Impact factor: 13.382

5.  An investigation of regional cerebral blood flow and tissue structure changes after acute administration of antipsychotics in healthy male volunteers.

Authors:  Peter C T Hawkins; Tobias C Wood; Anthony C Vernon; Alessandro Bertolino; Fabio Sambataro; Juergen Dukart; Emilio Merlo-Pich; Celine Risterucci; Hanna Silber-Baumann; Eamonn Walsh; Ndabezinhle Mazibuko; Fernando O Zelaya; Mitul A Mehta
Journal:  Hum Brain Mapp       Date:  2017-10-23       Impact factor: 5.038

6.  Effects of Ketamine on Resting-State EEG Activity and Their Relationship to Perceptual/Dissociative Symptoms in Healthy Humans.

Authors:  Sara de la Salle; Joelle Choueiry; Dhrasti Shah; Hayley Bowers; Judy McIntosh; Vadim Ilivitsky; Verner Knott
Journal:  Front Pharmacol       Date:  2016-09-27       Impact factor: 5.810

7.  A randomized, placebo-controlled, phase 1 study to evaluate the effects of TAK-063 on ketamine-induced changes in fMRI BOLD signal in healthy subjects.

Authors:  Deborah A Yurgelun-Todd; Perry F Renshaw; Paul Goldsmith; Tolga Uz; Thomas A Macek
Journal:  Psychopharmacology (Berl)       Date:  2019-11-26       Impact factor: 4.530

8.  Emotional Experience and Awareness of Self: Functional MRI Studies of Depersonalization Disorder.

Authors:  Nick Medford; Mauricio Sierra; Argyris Stringaris; Vincent Giampietro; Michael J Brammer; Anthony S David
Journal:  Front Psychol       Date:  2016-06-02

9.  Methamphetamine dependence with and without psychotic symptoms: A multi-modal brain imaging study.

Authors:  Daniella Vuletic; Patrick Dupont; Frances Robertson; James Warwick; Jan Rijn Zeevaart; Dan J Stein
Journal:  Neuroimage Clin       Date:  2018-10-22       Impact factor: 4.881

10.  Effects of N-acetylcysteine on brain glutamate levels and resting perfusion in schizophrenia.

Authors:  Grant McQueen; John Lally; Tracy Collier; Fernando Zelaya; David J Lythgoe; Gareth J Barker; James M Stone; Philip McGuire; James H MacCabe; Alice Egerton
Journal:  Psychopharmacology (Berl)       Date:  2018-08-23       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.